Showing results (121-130 of 182) with videos related to
Sort By:
Pageof 19
Carcinogenesis|March 27, 2009
Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosisPenelope A Bradbury, Rihong Zhai, Jessica Hopkins, et al.The Oncologist|January 5, 2019
Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review StudyMatthew H Kulke, Al B Benson, Arvind Dasari, et al.The Oncologist|January 6, 2019
Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review StudyArvind Dasari, Emily K Bergsland, Al B Benson, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancerP C Enzinger, D P Ryan, J W Clark, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Prognostic significance of MTOR pathway component expression in neuroendocrine tumorsZhi Rong Qian, Monica Ter-Minassian, Jennifer A Chan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518James C Yao, Katherine A Guthrie, Cesar Moran, et al.The Oncologist|January 3, 2012
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow, Aram F Hezel, Thomas A Abrams, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsMatthew H Kulke, Emily K Bergsland, David P Ryan, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 18, 2008
A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studiesPenelope A Bradbury, Rebecca Suk Heist, Matthew H Kulke, et al.JCO Precision Oncology|January 7, 2022
Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs)Kimberly Perez, Matthew H Kulke, Anu Chittenden, et al.Pageof 19